Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | USP2 | O75604 | 6/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | THPO | P40225 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | KCNK2 | O95069 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 8/20 | 0.98 |
| ▸ | MEN1 | O00255 | 7/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.98 |
| ▸ | RAD52 | P43351 | 3/20 | 0.98 |
| ▸ | GMNN | O75496 | 3/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.98 |
| ▸ | HTR1A | P08908 | 4/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| E-Flupentixol SCHEMBL30596168 | 1.00 | CYP3A4 (1.00) | CYP3A4USP2SIGMAR1CYP2D6MAPK1 | |
| Z-Flupentixol SCHEMBL34200 | 1.00 | CYP3A4 (1.00) | CYP3A4USP2SIGMAR1CYP2D6MAPK1 | |
| E-Flupentixol SCHEMBL145726 | 1.00 | CYP3A4 (1.00) | CYP3A4USP2SIGMAR1CYP2D6MAPK1 | |
| E-Flupentixol SCHEMBL29598791 | 1.00 | CYP3A4 (1.00) | CYP3A4USP2SIGMAR1CYP2D6MAPK1 | |
| Z-Flupentixol SCHEMBL29361845 | 1.00 | CYP3A4 (1.00) | CYP3A4USP2SIGMAR1CYP2D6MAPK1 | |
| E-Flupentixol SCHEMBL414352 | 1.00 | CYP3A4 (1.00) | CYP3A4USP2SIGMAR1CYP2D6MAPK1 | |
| E-Flupentixol SCHEMBL11427109 | 0.99 | LMNA (1.00) | CYP3A4USP2SIGMAR1CYP2D6MAPK1 | |
| Z-Flupentixol SCHEMBL719323 | 0.99 | LMNA (1.00) | CYP3A4USP2SIGMAR1CYP2D6MAPK1 | |
| E-Flupentixol SCHEMBL1230220 | 0.99 | LMNA (1.00) | CYP3A4USP2SIGMAR1CYP2D6MAPK1 | |
| Z-Flupentixol SCHEMBL1153162 | 0.99 | LMNA (1.00) | CYP3A4USP2SIGMAR1CYP2D6MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595284-B2 | Amatoxin antibody-drug conjugates and uses thereof | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2026-04-07 | — | — | US | disclosed |
| US-20260078148-A1 | AMATOXIN ANTIBODY-DRUG CONJUGATES AND USES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2026-03-19 | — | — | US | disclosed |
| US-12559593-B2 | Dual cure sealants | PRC-DESOTO INTERNATIONAL, INC. (CA) | 2026-02-24 | — | — | US | disclosed |
| US-20260014202-A1 | THERAPEUTIC METHODS USING ANTIBODY DRUG CONJUGATES (ADCS) | REGENERON PHARMACEUTICALS, INC. | 2026-01-15 | — | — | US | disclosed |
| US-12480051-B2 | Polymerizable liquid crystal compound, polymerizable composition, polymer, retardation film, method for producing retardation film, transfer laminate, optical member, method for producing optical member, and display device | DAI NIPPON PRINTING CO., LTD. (JP) | 2025-11-25 | — | — | US | disclosed |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE LTD (SG) | 2025-09-04 | — | — | US | disclosed |
| WO-2025120013-A1 | COMPOSITIONS AND METHODS FOR TREATING DEPRESSION DISORDERS | NOVARTIS AG (CH) | 2025-06-12 | — | — | WO | disclosed |
| EP-4531851-A1 | SUBCUTANEOUS ADMINISTRATION OF ONFASPRODIL AND DOSING METHODS FOR USE IN THE TREATMENT OF DEPRESSION DISORDERS | Novartis AG (CH) | 2025-04-09 | — | — | EP | disclosed |
| US-12197915-B2 | Parallel instruction demarcator | ONNIVATION LLC (US) | 2025-01-14 | — | — | US | disclosed |
| US-20240360238-A1 | COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD117+ CELLS | Magenta Therapeutics, Inc. | 2024-10-31 | — | — | US | disclosed |
| US-20230135930-A1 | AMATOXIN ANTIBODY-DRUG CONJUGATES AND USES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2023-05-04 | — | — | US | disclosed |
| CN-115835882-A | Targeting ABCB5 in glioblastoma multiforme | 儿童医学中心公司 | 2023-03-21 | — | — | CN | disclosed |
| US-11560518-B2 | Polymerizable liquid crystal compound, polymerizable composition, polymer, retardation film, method for producing retardation film, transfer laminate, optical member, method for producing optical member, and display device | DAI NIPPON PRINTING CO., LTD. (JP) | 2023-01-24 | — | — | US | disclosed |
| US-20220380383-A1 | NEUROPROTECTIVE PDI MODULATING SMALL MOLECULES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-12-01 | — | — | US | disclosed |
| EP-3737684-B1 | 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-11-16 | — | — | EP | disclosed |
| US-20220226493-A1 | ANTHRACYCLINE ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Magenta Therapeutics, Inc. | 2022-07-21 | — | — | US | disclosed |
| US-20220175944-A1 | ANTI-CD117 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Magenta Therapeutics, Inc. | 2022-06-09 | — | — | US | disclosed |
| US-20220177577-A1 | ANTI-CD117 ANTIBODY DRUG CONJUGATES AND USES THEREOF | Magenta Therapeutics, Inc. | 2022-06-09 | — | — | US | disclosed |
| US-20220175946-A1 | CONDITIONING METHODS FOR GENE THERAPY | REGENERON PHARMACEUTICALS, INC. | 2022-06-09 | — | — | US | disclosed |
| US-20220137971-A1 | INSTRUCTION LENGTH BASED PARALLEL INSTRUCTION DEMARCATOR | ONNIVATION LLC (US) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135930-A1 | AMATOXIN ANTIBODY-DRUG CONJUGATES AND USES THEREOF | MYADM, FUT7, SIGLEC7 | CYP3A4 4630/4885USP2 4664/4885SIGMAR1 4415/4885 |
| US-11560518-B2 | Polymerizable liquid crystal compound, polymerizable composition, polymer, retardation film, method for producing retardation film, transfer laminate, optical member, method for producing optical member, and display device | TRRAP, CDH1, LRRFIP1 | CYP3A4 3686/4885USP2 3262/4885SIGMAR1 4403/4885 |
| US-12595284-B2 | Amatoxin antibody-drug conjugates and uses thereof | HLA-DRB1, CD2, CD74 | CYP3A4 4415/4885USP2 4230/4885SIGMAR1 4265/4885 |
| US-12559593-B2 | Dual cure sealants | DUOX2, DUOX1, GPX4 | CYP3A4 1946/4885USP2 69/4885SIGMAR1 1113/4885 |
| US-20220175944-A1 | ANTI-CD117 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | ITGB7, KIT, CD2 | CYP3A4 2103/4885USP2 3064/4885SIGMAR1 3184/4885 |
| US-12480051-B2 | Polymerizable liquid crystal compound, polymerizable composition, polymer, retardation film, method for producing retardation film, transfer laminate, optical member, method for producing optical member, and display device | TRRAP, CDH1, LRRFIP1 | CYP3A4 3686/4885USP2 3262/4885SIGMAR1 4403/4885 |
| US-20220177577-A1 | ANTI-CD117 ANTIBODY DRUG CONJUGATES AND USES THEREOF | SIGLEC7, FUT7, ITGB7 | CYP3A4 2882/4885USP2 4192/4885SIGMAR1 3888/4885 |
| US-20260014202-A1 | THERAPEUTIC METHODS USING ANTIBODY DRUG CONJUGATES (ADCS) | CD2, MYADM, CD47 | CYP3A4 3603/4885USP2 3576/4885SIGMAR1 3938/4885 |
| US-20260078148-A1 | AMATOXIN ANTIBODY-DRUG CONJUGATES AND USES THEREOF | CD2, CD74, CD99 | CYP3A4 3837/4885USP2 3885/4885SIGMAR1 3759/4885 |
| US-20220175946-A1 | CONDITIONING METHODS FOR GENE THERAPY | CD74, CD2, CD44 | CYP3A4 4834/4885USP2 2723/4885SIGMAR1 3864/4885 |
| US-20220380383-A1 | NEUROPROTECTIVE PDI MODULATING SMALL MOLECULES AND METHODS OF USE THEREOF | NLN, PDIA5, PRNP | CYP3A4 4370/4885USP2 1221/4885SIGMAR1 422/4885 |
| US-20240360238-A1 | COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD117+ CELLS | CD47, SIGLEC7, MYADM | CYP3A4 4602/4885USP2 2362/4885SIGMAR1 4571/4885 |
| US-20220226493-A1 | ANTHRACYCLINE ANTIBODY-DRUG CONJUGATES AND USES THEREOF | FUT7, ITGB7, CD2 | CYP3A4 2169/4885USP2 2683/4885SIGMAR1 3765/4885 |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | UPF1, NLN, BRCA1 | CYP3A4 4576/4885USP2 593/4885SIGMAR1 2471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.